LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Lista de Ações・Denali Therapeutics Inc

Denali Therapeutics Inc

Abrir

SetorSaúde

20.35 -0.39

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

20.23

Máximo

21.71

Indicadores-chave
By Trading Economics
Rendimento	102K -128M
EPS	-0.69
Funcionários	507
EBITDA	-9.8M -135M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+81.68% upside

Dividendos
By Dow Jones
Próximos Ganhos	7 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	136M 3.1B
Abertura anterior	20.74
Fecho anterior	20.35

Sentimento de Notícias

By Acuity

27%

73%

61 / 344 Ranking em Healthcare

Denali Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

9 de jun. de 2026, 23:49 UTC

Conversa de Mercado

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 de jun. de 2026, 23:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 de jun. de 2026, 23:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 de jun. de 2026, 23:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 de jun. de 2026, 23:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 de jun. de 2026, 23:35 UTC

Conversa de Mercado

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 de jun. de 2026, 22:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 de jun. de 2026, 22:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 de jun. de 2026, 22:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 de jun. de 2026, 22:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 de jun. de 2026, 20:51 UTC

Ganhos

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

9 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de jun. de 2026, 20:09 UTC

Conversa de Mercado

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 de jun. de 2026, 19:36 UTC

Conversa de Mercado

Cattle Climbs as Crude Oil Falls -- Market Talk

9 de jun. de 2026, 19:32 UTC

Conversa de Mercado

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 de jun. de 2026, 19:25 UTC

Conversa de Mercado

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 de jun. de 2026, 19:00 UTC

Conversa de Mercado

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 de jun. de 2026, 18:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 de jun. de 2026, 18:47 UTC

Conversa de Mercado

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 de jun. de 2026, 18:37 UTC

Conversa de Mercado

Canada's Cooling Trade With the U.S. -- Market Talk

9 de jun. de 2026, 18:27 UTC

Conversa de Mercado

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 de jun. de 2026, 17:35 UTC

Conversa de Mercado

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 de jun. de 2026, 17:30 UTC

Conversa de Mercado

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 de jun. de 2026, 16:34 UTC

Conversa de Mercado

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

9 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Health Care Roundup: Market Talk

9 de jun. de 2026, 15:28 UTC

Conversa de Mercado

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 de jun. de 2026, 15:25 UTC

Conversa de Mercado

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Comparação entre Pares

Variação de preço

Denali Therapeutics Inc Previsão

Preço-alvo

By TipRanks

81.68% parte superior

Previsão para 12 meses

Média 35.5 USD 81.68%

Máximo 42 USD

Mínimo 23 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Denali Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

13 ratings

Comprar

Manter

Vender

Com base em 13 analistas que deram avaliações de ações para Denali Therapeutics Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

61 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.